<DOC>
	<DOCNO>NCT02727101</DOCNO>
	<brief_summary>The goal present study evaluate ( `` screen '' ) large number ( 12 ) different dual therapy perampanel + another AED ( `` PMP+ '' ) large , 75-100 % seizure frequency reduction . The design study differ usual AED study . The study ( ) open label , ( ii ) small n per group , n=6 , ( iii ) outcome measure 'blockbuster effect ' : ( ) ≥75 seizure frequency reduction ; ( b ) seizure freedom .</brief_summary>
	<brief_title>Perampanel Treatment Adults With Refractory Focal Epilepsy : Pilot Study .</brief_title>
	<detailed_description>Investigators compare rate seizure freedom &gt; 75 % seizure frequency reduction among 12 treatment arm consist 6 subject refractory focal epilepsy treat perampanel one AED ( `` PMP+ '' ) . Treatment arm include ( 1 ) Perampanel +phenobarbital , ( 2 ) PMP+valproate , ( 3 ) PMP+ lamotrigine , ( 4 ) PMP + topiramate , ( 5 ) PMP + tiagabine , ( 6 ) PMP + levetiracetam , ( 7 ) PMP + zonisamide , ( 8 ) PMP + pregabalin , ( 9 ) PMP + lacosamide , ( 10 ) PMP+ clobazam , ( 11 ) PMP + ezogabine ; ( 12 ) PMP + eslicarbazepine . Each group 6 follow 12 week baseline observation baseline medication . Seizure frequency count , use subject ' self-reported seizure diary . PMP titrate 8-12 mg/day , final dose determine side effect tolerability PMP 8-12 mg/day dos . Titration occur rate 2 mg/week two week ( accordance FDA labeling ) , tolerate . Subjects observe 12 week maintenance treatment target PMP dose . Seizure frequency compare 12 week baseline observation 12 week maintenance treatment .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Lamotrigine</mesh_term>
	<mesh_term>Zonisamide</mesh_term>
	<mesh_term>Phenobarbital</mesh_term>
	<criteria>1 . Age 1865 2 . Stable focal epilepsy , partial complex seizure include partial complex seizure without secondary generalization , partial simple seizure clear motor component without secondary generalization , partial simple seizure secondary generalization . 3 . Stable dose least 30 day choose background AED dose 4 . Epilepsy duration &gt; 2 year 5 . Past/current treatment &gt; 4 AEDs . Vagal nerve stimulator treatment allow count AED . VNS set must stable 3 month prior enrollment . 6 . Seizure frequency ≥1/month 1 . Primary generalize epilepsy 2 . Simple partial seizure without motor component secondary generalization 3 . Nonepileptic seizure 4 . Progressive neurological disease include grow neoplasm , CNS degenerative disorder include Alzheimer 's disease , form dementia 5 . Any systemic illness unstable medical condition might pose additional risk , include renal liver disease , clinically uncontrolled cardiac disease , unstable metabolic endocrine disturbance , active systemic cancer 6 . Change dose Antiepileptic Drug within 30 day prior enrollment 7 . Psychosis within six month enrollment . 8 . Active drug alcohol dependence factor , opinion site investigator would interfere adherence study requirement ; 9 . Pregnancy 10 . Use CNSactive investigational drug within 3 month enrollment . 11 . Inability unwillingness subject legal guardian/representative give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Focal epilepsy , Perampanel</keyword>
</DOC>